Drug Pipeline

March 08, 2021

Will emerging variants make the leading vaccines less protective?

February 09, 2021

The COPD Foundation is calling for a change in clinical trial design that would test experimental therapies in subsets of patients.

February 01, 2021

Opinion piece by MHE's Editorial Advisory Board Member and CEO of The Pharmacy Group, Perry Cohen. Perry discusses the response differences and vague similarities between the countries and addresses the continuous question, "What is the new normal?"

January 15, 2021

The industry is adjusting to the pandemic, but FDA approvals could dip this year. Several new drugs for atopic dermatitis may get the agency’s green light.

December 16, 2020

Pre-pandemic momentum helped keep the number of novel therapies approved by the FDA high, and then COVID-19 tested just how fast the pipeline could adjust and expand.

November 27, 2020

Results of APOLLO and REACH3 trials are scheduled for presentation at the American Society of Hematology meeting next month are expected to garner attention.

September 28, 2020

Negative results for semorinemab have deflated some of the hopes for a tau as a target, although a winning strategy Alzheimer's may involve hitting several targets at once, including tau.

August 23, 2020

FDA actions for the week ending August 21, 2020, include a hearing set for a drug that could limit weight gain often associated with treatment for serious mental illness.

August 16, 2020

Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.

August 02, 2020

In a busy week, FDA approved ground-breaking therapies in hematologic cancers and issued Orphan Drug designations in areas of significant unmet need.

July 31, 2020

Potential agents to battle inflammation and other processes move through development pipeline.

July 29, 2020

As several COVID-19 vaccine candidates are now in the late phase of clinical trials, MHE is sharing a few stories that have covered the infamous virus' vaccine development journey.

July 24, 2020

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

July 23, 2020

Dr. David Ho, who developed the HIV cocktail, has isolated antibodies he says could be used to create treatments for COVID-19.

July 19, 2020

How real-world evidence will help FDA develop a vaccine.

July 18, 2020

Heart disease drugs were in the news this week.

July 14, 2020

The fast-evolving field of precision medicine offers the promise of more effective treatments and better outcomes, and it’s time that we collaborate to keep outdated clinical and reimbursement practices from slowing it down.

July 12, 2020

Patients with diabetic macular edema whose vision remains impaired even with the best available treatments may soon have a combination therapy.

July 11, 2020

Drug development in key areas of unmet need hit milestones this week, with Biogen, AstraZeneca, and Jaguar Health announcing regulatory steps with the FDA.

July 01, 2020

In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.